PepGen Inc. (PEPG)
- Previous Close
1.2900 - Open
1.2800 - Bid 1.2000 x 100
- Ask 1.3100 x 100
- Day's Range
1.2500 - 1.3554 - 52 Week Range
0.8800 - 19.2980 - Volume
83,764 - Avg. Volume
2,788,900 - Market Cap (intraday)
41.228M - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8500 - Earnings Date May 12, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.20
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
pepgen.comRecent News: PEPG
View More
Performance Overview: PEPG
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEPG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEPG
View MoreValuation Measures
Market Cap
41.23M
Enterprise Value
-60.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.35
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.56%
Return on Equity (ttm)
-79.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-89.98M
Diluted EPS (ttm)
-2.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
120.19M
Total Debt/Equity (mrq)
15.73%
Levered Free Cash Flow (ttm)
-50.85M